Geron (GERN) Liabilities and Shareholders Equity (2010 - 2026)
Geron's (GERN) quarterly Liabilities and Shareholders Equity came in at $534.1 million in Q1 2026, down 5.04% year-on-year from $562.4 million in Q1 2025, and down 6.38% quarter-over-quarter from $570.5 million in Q4 2025.
Geron (GERN) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Geron has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $534.1 million for Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $534.1 million, down 5.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 8.62% YoY), and the FY2025 annual result was $570.5 million, down 3.91% from the prior year.
- Liabilities and Shareholders Equity came in at $534.1 million for Q1 2026 at Geron, down from $570.5 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $593.8 million in Q4 2024 to a low of $190.6 million in Q4 2022.
- The 5-year median for Liabilities and Shareholders Equity is $445.0 million (2024), against an average of $427.5 million.
- Across the five-year window, Liabilities and Shareholders Equity slipped 23.27% in 2022 and surged 114.13% in 2023, its largest moves.
- Geron's Liabilities and Shareholders Equity stood at $190.6 million in 2022, then surged by 106.78% to $394.1 million in 2023, then jumped by 50.68% to $593.8 million in 2024, then fell by 3.91% to $570.5 million in 2025, then decreased by 6.38% to $534.1 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $534.1 million (Q1 2026), $570.5 million (Q4 2025), and $567.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 33.89 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 23.64 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 640.56 Mn |
| 10 | Geron | 729,618.77 | 729,618.77 | - | 534.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 534.12 Mn |
| Dec 31, 2025 | 570.54 Mn |
| Sep 30, 2025 | 567.38 Mn |
| Jun 30, 2025 | 555.20 Mn |
| Mar 31, 2025 | 562.45 Mn |
| Dec 31, 2024 | 593.78 Mn |
| Sep 30, 2024 | 444.95 Mn |
| Jun 30, 2024 | 449.40 Mn |
| Mar 31, 2024 | 482.07 Mn |
| Dec 31, 2023 | 394.08 Mn |
| Sep 30, 2023 | 413.02 Mn |
| Jun 30, 2023 | 415.30 Mn |
| Mar 31, 2023 | 424.88 Mn |
| Dec 31, 2022 | 190.58 Mn |
| Sep 30, 2022 | 232.61 Mn |
| Jun 30, 2022 | 238.16 Mn |
| Mar 31, 2022 | 198.42 Mn |
| Dec 31, 2021 | 226.03 Mn |
| Sep 30, 2021 | 229.10 Mn |
| Jun 30, 2021 | 252.18 Mn |